These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 23327881

  • 41. Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study.
    Fischer-Betz R, Chehab G, Sander O, Vordenbäumen S, Voiculescu A, Brinks R, Schneider M.
    J Rheumatol; 2012 Nov; 39(11):2111-7. PubMed ID: 22984276
    [Abstract] [Full Text] [Related]

  • 42. Long-term Safety and Effectiveness of Tacrolimus in Patients With Lupus Nephritis: 5-year Interim Postmarketing Surveillance Study in Japan (TRUST).
    Takeuchi T, Wakasugi N, Uno S, Makino H.
    J Rheumatol; 2021 Jan 01; 48(1):74-81. PubMed ID: 32238515
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. The prognosis of biopsy-proven lupus nephritis in chinese patients: long term follow-up of 86 cases.
    Shen K, Yu Y, Tang Z, Liu Z, Li L.
    Chin Med J (Engl); 1997 Jul 01; 110(7):502-7. PubMed ID: 9594205
    [Abstract] [Full Text] [Related]

  • 45. Efficacy and safety of multitarget therapy with mizoribine and tacrolimus for systemic lupus erythematosus with or without active nephritis.
    Nomura A, Shimizu H, Kishimoto M, Suyama Y, Rokutanda R, Ohara Y, Yamaguchi K, Okada M.
    Lupus; 2012 Nov 01; 21(13):1444-9. PubMed ID: 22917589
    [Abstract] [Full Text] [Related]

  • 46. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.
    Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM.
    Arthritis Rheum; 2005 Feb 01; 52(2):501-13. PubMed ID: 15693003
    [Abstract] [Full Text] [Related]

  • 47. Interleukin-2 profiles shortly after tacrolimus conversion from a twice-daily to once-daily regimen.
    Meçule A, Tinti F, Bachetoni A, Poli L, D'Alessandro M, Alessandri C, Umbro I, Nofroni I, Berloco PB, Mitterhofer AP.
    Transplant Proc; 2011 May 01; 43(4):1017-9. PubMed ID: 21620040
    [Abstract] [Full Text] [Related]

  • 48. Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study.
    Kremer JM, Habros JS, Kolba KS, Kaine JL, Borton MA, Mengle-Gaw LJ, Schwartz BD, Wisemandle W, Mekki QA, Tacrolimus-Methotrexate Rheumatoid Arthritis Study Group.
    Arthritis Rheum; 2003 Oct 01; 48(10):2763-8. PubMed ID: 14558080
    [Abstract] [Full Text] [Related]

  • 49. Post-marketing surveillance study of the long-term use of mizoribine for the treatment of lupus nephritis: 2-Year results.
    Takeuchi T, Okada K, Yoshida H, Yagi N.
    Mod Rheumatol; 2018 Jan 01; 28(1):85-94. PubMed ID: 28722500
    [Abstract] [Full Text] [Related]

  • 50. Comparison of high and low dose of cyclophosphamide in lupus nephritis patients: a long-term randomized controlled trial.
    Mitwalli AH, Al Wakeel JS, Hurraib S, Aisha A, Al Suwaida A, Alam A, Hammad D, Sulimani F, Memon NA, Askar A, Al Tuwaijri A, Qudsi A.
    Saudi J Kidney Dis Transpl; 2011 Sep 01; 22(5):935-40. PubMed ID: 21912022
    [Abstract] [Full Text] [Related]

  • 51. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients.
    Nakamura Y, Hama K, Katayama H, Soga A, Toraishi T, Yokoyama T, Kihara Y, Jojima Y, Konno O, Iwamoto H, Takeuchi H, Hirano T, Shimazu M.
    Transplant Proc; 2012 Jan 01; 44(1):124-7. PubMed ID: 22310595
    [Abstract] [Full Text] [Related]

  • 52. Tacrolimus: a new therapy for steroid-resistant nephrotic syndrome in children.
    Gulati S, Prasad N, Sharma RK, Kumar A, Gupta A, Baburaj VP.
    Nephrol Dial Transplant; 2008 Mar 01; 23(3):910-3. PubMed ID: 18039644
    [Abstract] [Full Text] [Related]

  • 53. Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis.
    Hogan J, Godron A, Baudouin V, Kwon T, Harambat J, Deschênes G, Niel O.
    Pediatr Nephrol; 2018 Jan 01; 33(1):111-116. PubMed ID: 28780657
    [Abstract] [Full Text] [Related]

  • 54. Renal outcome and predictors of clinical renal involvement in patients with silent lupus nephritis.
    Wada Y, Ito S, Ueno M, Nakano M, Arakawa M, Gejyo F.
    Nephron Clin Pract; 2004 Jan 01; 98(4):c105-11. PubMed ID: 15627787
    [Abstract] [Full Text] [Related]

  • 55. Health-related utility among adults with atopic dermatitis treated with 0.1% tacrolimus ointment as maintenance therapy over the long term: findings from the Protopic CONTROL study.
    Poole CD, Chambers C, Sidhu MK, Currie CJ.
    Br J Dermatol; 2009 Dec 01; 161(6):1335-40. PubMed ID: 19754867
    [Abstract] [Full Text] [Related]

  • 56. Predictors of renal flares and long-term renal outcome in patients with lupus nephritis: results from daily clinical practice.
    Ligtenberg G, Arends S, Stegeman CA, de Leeuw K.
    Clin Exp Rheumatol; 2022 Jan 01; 40(1):33-38. PubMed ID: 33822705
    [Abstract] [Full Text] [Related]

  • 57. Effects of concomitant hepatitis C virus infection in patients with underlying lupus nephritis on long-term renal outcome.
    Mitwalli AH, Hayat A, Alwakeel J, Hammad D.
    Nephrol Dial Transplant; 2012 Feb 01; 27(2):627-32. PubMed ID: 21771749
    [Abstract] [Full Text] [Related]

  • 58. Mizoribine therapy for patients with lupus nephritis: the association between peak mizoribine concentration and clinical efficacy.
    Kuroda T, Hirose S, Tanabe N, Sato H, Nakatsue T, Ajiro J, Wada Y, Murakami S, Hasegawa H, Ito S, Sakatsume M, Nakano M, Gejyo F.
    Mod Rheumatol; 2007 Feb 01; 17(3):206-12. PubMed ID: 17564775
    [Abstract] [Full Text] [Related]

  • 59. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial.
    Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M, Dinda A.
    Am J Kidney Dis; 2009 May 01; 53(5):760-9. PubMed ID: 19268410
    [Abstract] [Full Text] [Related]

  • 60. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
    Mok CC, Ying KY, Ng WL, Lee KW, To CH, Lau CS, Wong RW, Au TC.
    Am J Med; 2006 Apr 01; 119(4):355.e25-33. PubMed ID: 16564783
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.